GSK 3 Inhibitor IX
Based on 17 publication(s) in Google Scholar
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
For research use only. We do not sell to patients.
- Purity: 99.47%
- CAS No.: 667463-62-9
- Formula: C16H10BrN3O2
- Molecular Weight:356.17
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) GSK 3 Inhibitor IX
More- Cell Res. 2022 Jun;32(6):513-529. [Abstract]
- Nat Commun. 2024 Jun 11;15(1):4969. [Abstract]
- Cell Death Differ. 2020 Mar;27(3):1119-1133. [Abstract]
- Chem Eng J. 19 November 2021, 133671.
- J Biomed Sci. 2026 May 15;33(1):51. [Abstract]
- Neoplasia. 2022 Dec:34:100839. [Abstract]
- J Transl Med. 2022 Oct 2;20(1):444. [Abstract]
- Cell Rep. 2020 Jan 14;30(2):497-509.e4. [Abstract]
- NPJ Regen Med. 2021 Sep 6;6(1):51. [Abstract]
- JCI Insight. 2025 Nov 13:e191606. [Abstract]
- ACS Biomater Sci Eng. 2021 Jan 11;7(1):232-241. [Abstract]
- Int J Mol Sci. 2026 Mar 14;27(6):2676. [Abstract]
- Aquat Toxicol. 2023 Jul:260:106588. [Abstract]
- Mol Cell Endocrinol. 2016 May 15:427:33-44. [Abstract]
- Mol Immunol. 2025 Oct:186:1-12. [Abstract]
- Vet Microbiol. 2026 Feb:313:110871. [Abstract]
- bioRxiv. 2025 March 10.
-
In Vivo Efficacy Study
-
WB
-
Cell Proliferation/Viability Assay
-
IF
-
IF
Biological Activity
|
GSK-3α 5 nM (IC50) |
GSK-3β 5 nM (IC50) |
CDK5/p35 80 nM (IC50) |
Cdk1/cyclin B 320 nM (IC50) |
cdk2/cyclin A 300 nM (IC50) |
Cdk4/cyclin D1 10 μM (IC50) |
MAPKK 10 μM (IC50) |
protein kinase Cα 12 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
5.2 μM
Compound: 17
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| HepG2 | IC50 |
5.3 μM
Compound: 3b
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 24 hrs by alamar blue assay
|
[PMID: 28743492] |
| HL-60 | IC50 |
5.4 μM
Compound: 17
|
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
Antiproliferative activity against human HL60 cells after 5 days by MTT assay
|
[PMID: 19783149] |
| Huh-7 | IC50 |
6.2 μM
Compound: 17
|
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| IMR-90 | IC50 |
1.9 μM
Compound: 17
|
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| K562 | IC50 |
1.3 μM
Compound: 17
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 19783149] |
| Monocyte | IC50 |
>3 μM
Compound: 15, 6BIO
|
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-8 expression
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-8 expression
|
[PMID: 24697244] |
| Monocyte | IC50 |
0.2 μM
Compound: 15, 6BIO
|
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-1beta expression
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-1beta expression
|
[PMID: 24697244] |
| Monocyte | IC50 |
0.5 μM
Compound: 15, 6BIO
|
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced TNFalpha expression
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced TNFalpha expression
|
[PMID: 24697244] |
| Monocyte | IC50 |
1.6 μM
Compound: 15, 6BIO
|
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-6 expression
Antiinflammatory activity against human monocytes assessed as reduction of LPS-induced IL-6 expression
|
[PMID: 24697244] |
| Oocyte | IC50 |
0.32 μM
Compound: 53
|
Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis
Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis
|
[PMID: 34161865] |
| Oocyte | IC50 |
0.32 μM
Compound: 6-bromoindirubin-3'-oxime
|
Inhibitory activity against cyclin dependent kinase 1-cyclinB from starfish (Marthasterias glacialis) oocytes
Inhibitory activity against cyclin dependent kinase 1-cyclinB from starfish (Marthasterias glacialis) oocytes
|
[PMID: 14761195] |
| Sf9 | IC50 |
0.014 μM
Compound: BIO
|
Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.041 μM
Compound: BIO
|
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.27 μM
Compound: BIO
|
Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.45 μM
Compound: BIO
|
Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
0.527 μM
Compound: BIO
|
Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| Sf9 | IC50 |
3.5 μM
Compound: BIO
|
Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay
|
[PMID: 30234987] |
| SH-SY5Y | EC50 |
>30 μM
Compound: 15, 6BIO
|
Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability
Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability
|
[PMID: 24697244] |
| SH-SY5Y | IC50 |
0.29 μM
Compound: 6BIO
|
Inhibition of GSK3-mediated beta-casein phosphorylation in human SH-SY5Y cells in presence of MG132 by Western blot analysis
Inhibition of GSK3-mediated beta-casein phosphorylation in human SH-SY5Y cells in presence of MG132 by Western blot analysis
|
[PMID: 18816110] |
| SH-SY5Y | IC50 |
10 μM
Compound: 6BIO
|
Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay
Death of human SH-SY5Y cells in absence of 20 uM Q-VD-OPh by MTS reduction assay
|
[PMID: 16854069] |
| SH-SY5Y | IC50 |
13 μM
Compound: 6BIO
|
Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay
Death of human SH-SY5Y cells in presence of 20 uM Q-VD-OPh by MTS reduction assay
|
[PMID: 16854069] |
| SH-SY5Y | IC50 |
18 μM
Compound: 6BIO
|
Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay
Survival of human SH-SY5Y cells after 24 hrs by MTS reduction assay
|
[PMID: 16854069] |
| SH-SY5Y | IC50 |
9 μM
Compound: 6BIO
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS reduction assay
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS reduction assay
|
[PMID: 18816110] |
| SH-SY5Y | IC50 |
9.5 μM
Compound: 6BIO
|
Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay
Survival of human SH-SY5Y cells after 48 hrs by MTS reduction assay
|
[PMID: 16854069] |
GSK 3 Inhibitor IX (BIO) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows > 16-fold selectivity over CDK5.
GSK 3 Inhibitor IX interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos[1].
In human and mouse embryonic stem cells, GSK 3 Inhibitor IX (BIO) maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. GSK 3 Inhibitor IX (BIO)-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells[2].
GSK 3 Inhibitor IX (BIO) promotes proliferation in mammalian cardiomyocytes[3].
GSK 3 Inhibitor IX (BIO) is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3, respectively. GSK 3 Inhibitor IX (BIO) selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 667463-62-9
-
Appearance Solid
-
Molecular Weight 356.17
-
Formula C16H10BrN3O2
-
Color Brown to red
-
SMILES
O/N=C(C1=CC=CC=C1N2)/C2=C3C(NC4=C/3C=CC(Br)=C4)=O
-
Synonyms
6-Bromoindirubin-3'-oxime; BIO; MLS 2052
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]2022 Jun;32(6):513-529. PMID: 35508506 -
Nat Commun
MYG1 drives glycolysis and colorectal cancer development through nuclear-mitochondrial collaboration. [Abstract]2024 Jun 11;15(1):4969. PMID: 38862489
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 11;15(1):4969. [Abstract]
GSK 3 Inhibitor IX (10 μM; 10 h), a GSK3β inhibitor, inhibited the MYG1-induced phosphorylation of PKM2 in HCT116 cells.
-
Cell Death Differ
The cross talk of two family members of β-TrCP in the regulation of cell autophagy and growth. [Abstract]2020 Mar;27(3):1119-1133. PMID: 31406304 -
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Chem Eng J. 19 November 2021, 133671.
GSK 3 Inhibitor IX (BIO) (0.1-40 μg/mL; 24 h) at concentrations ranging from 0.1 to 20 μg/mL enhanced cell viability, and 10 μg/mL BIO had the maximal cytoprotective effect.
-
J Biomed Sci
SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production. [Abstract]2026 May 15;33(1):51. PMID: 42141450 -
Neoplasia
2022 Dec:34:100839. PMID: 36240645 -
J Transl Med
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]2022 Oct 2;20(1):444. PMID: 36184616 -
Cell Rep
2020 Jan 14;30(2):497-509.e4. PMID: 31940492 -
NPJ Regen Med
Cyclic pulsation stress promotes bone formation of tissue engineered laminae through the F-actin/YAP-1/β-Catenin signaling axis. [Abstract]2021 Sep 6;6(1):51. PMID: 34489466
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: NPJ Regen Med. 2021 Sep 6;6(1):51. [Abstract]
GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) (2.0 μM) recovered the expression of Osterix and VEGF-A inhibited by YAP-1 knockdown in MSCs.
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: NPJ Regen Med. 2021 Sep 6;6(1):51. [Abstract]
Treatment with GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) (2.0 μM) reduced the degradation and promoted the nuclear translocation of β-Catenin in the CSFP + YAP1-knockdown MSC.
-
JCI Insight
Aebp1 loss in osteoprogenitors leads to skeletal defects resembling Ehlers-Danlos Syndrome by diminishing Wnt/β-catenin signaling. [Abstract]2025 Nov 13:e191606. PMID: 41231548
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: JCI Insight. 2025 Nov 13:e191606. [Abstract]
GSK 3 Inhibitor IX (BIO) (10 mL/kg; i.p.) treatment substantially ameliorated skeletal abnormalities and augmented bone formation in Aebp1OsxCre mice at P0 and P21.
-
ACS Biomater Sci Eng
6-Bromoindirubin-3'-oxime Promotes Osteogenic Differentiation of Periodontal Ligament Stem Cells and Facilitates Bone Regeneration in a Mouse Periodontitis Model. [Abstract]2021 Jan 11;7(1):232-241. PMID: 33320531 -
Int J Mol Sci
Fluoxetine Repurposing Mitigates Alzheimer's Disease Pathology via the GSK3β-CREB-ADAM10 Axis. [Abstract]2026 Mar 14;27(6):2676. PMID: 41898539 -
Aquat Toxicol
Tris(1,3-dichloro-2-propyl) Phosphate Inhibits Early Embryonic Development by Binding to Gsk-3β Protein in Zebrafish. [Abstract]2023 Jul:260:106588. PMID: 37267805 -
Mol Cell Endocrinol
Synergistic role of β-catenin1 and 2 in ovarian differentiation and maintenance of female pathway in Nile tilapia. [Abstract]2016 May 15:427:33-44. PMID: 26948949
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2016 May 15:427:33-44. [Abstract]
Immunohistochemistry analyses of gene expression in the in vitro cultured tilapia ovaries obtained from 20 and 180 dah XX fish. Gonads were collected from 180 dah XX fish and cultured in L15 medium with 30 μg/ml Dkk1. Cyp19a1a remained unchanged in the presence of Dkk1. Dkk1 upregulated Cyp11b2 and Dmrt1 expression, which was abolished by simultaneous treatment with GSK 3 Inhibitor IX (Bio) (15-30 μg/mL). The positive signal corresponds to the brownish color. Dkk1, antagonist of canonical Wnt/β-cat signal pathway; Bio, agonist of canonical Wnt/β-cat signal pathway.
GSK 3 Inhibitor IX purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2016 May 15:427:33-44. [Abstract]
Real-time PCR analysis of cyp11b2 and dmrt1 expression in the in vitro cultured 180 dah tilapia gonad with Dkk1 (0-50 μg/mL) and with or without GSK 3 Inhibitor IX (Bio) (15-30 μg/mL). Gonads were collected from 180 dah XX fish and cultured in L15 medium with 30 μg/mL Dkk1. Dkk1 upregulated cyp11b2 and dmrt1 expression in a dose dependent manner, which was abolished by simultaneous treatment with Bio.
-
Mol Immunol
Luteolin attenuates type 2 inflammation in asthmatic mice induced by OVA by regulating IL-33/ST2- GSK3β-M2 macrophage polarization. [Abstract]2025 Oct:186:1-12. PMID: 40752323 -
Vet Microbiol
Phosphorylation of T425 and methylation of R426 synergistically regulate IBDV VP1 function and viral replication. [Abstract]2026 Feb:313:110871. PMID: 41506171 -
Solvent & Solubility
DMSO : ≥ 23 mg/mL (64.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), GSK 3 Inhibitor IX (BIO) (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches appr 70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000× g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT, mouse anti-phospho-β-catenin, mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BALB/c mice (at 6-8 weeks old) and immunodeficient NOD/SCID/IL2Rgamma null (NSG) mice (female at 6-8 weeks old) are used in the assay. A2058 human melanoma cells at 5×106 cells in serum free medium are inoculated subcutaneously into the dorsal area of NSG mice to create xenograft model. When tumors become palpable, 6 GSK 3 Inhibitor IX (BIO) or vehicle control is administered via oral gavage once daily at 50 mg/kg body weight. Tumor growth is monitored every other day. Tumor volumes are measured every 3 to 4 days. Tumor volumes are calculated using the formula: 0.5 × (larger diameter) × (small diameter)2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Meijer L, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003 Dec;10(12):1255-66. [Content Brief]
[2]. Sato N, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004 Jan;10(1):55-63. Epub 2003 Dec 21. [Content Brief]
[3]. Tseng AS, et al. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol. 2006 Sep;13(9):957-63. [Content Brief]
[4]. Liu L1, et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res. 2011 Jun 1;71(11):3972-9 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8076 mL | 14.0382 mL | 28.0765 mL | 70.1912 mL |
| 5 mM | 0.5615 mL | 2.8076 mL | 5.6153 mL | 14.0382 mL | |
| 10 mM | 0.2808 mL | 1.4038 mL | 2.8076 mL | 7.0191 mL | |
| 15 mM | 0.1872 mL | 0.9359 mL | 1.8718 mL | 4.6794 mL | |
| 20 mM | 0.1404 mL | 0.7019 mL | 1.4038 mL | 3.5096 mL | |
| 25 mM | 0.1123 mL | 0.5615 mL | 1.1231 mL | 2.8076 mL | |
| 30 mM | 0.0936 mL | 0.4679 mL | 0.9359 mL | 2.3397 mL | |
| 40 mM | 0.0702 mL | 0.3510 mL | 0.7019 mL | 1.7548 mL | |
| 50 mM | 0.0562 mL | 0.2808 mL | 0.5615 mL | 1.4038 mL | |
| 60 mM | 0.0468 mL | 0.2340 mL | 0.4679 mL | 1.1699 mL |